title: The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.
abstract: BACKGROUND
  Irradiation of the pituitary is widely considered the most appropriate treatment for patients with Cushing's disease in whom transsphenoidal microsurgery has been unsuccessful. However, there is little information about the long-term efficacy of this treatment.
  
  
  METHODS
  We used external pituitary radiation to treat 30 adult patients with persistent or recurrent Cushing's disease after unsuccessful transsphenoidal surgery. The mean (+/-SD) dose of radiation was 50+/-1 Gy. Pituitary and adrenal function was assessed every six months after radiation therapy. Remission was defined as the regression of symptoms and signs of Cushing's syndrome, normal urinary cortisol excretion, and a low plasma cortisol concentration in the morning after the administration of 1 mg of dexamethasone at midnight.
  
  
  RESULTS
  Twenty-five patients (83 percent) had remissions during a median follow-up of 42 months (range, 18 to 114). The remissions began 6 to 60 months after radiation therapy, but in most cases (22 patients) remission occurred during the first 2 years. None of the 25 patients had a relapse of Cushing's disease after remission was achieved. There was no relation between the response to radiotherapy and sex, age, urinary cortisol excretion before radiotherapy, the interval between surgery and radiotherapy, whether a pituitary adenoma was found by pathological examination, or tumor size. Seventeen patients had a deficiency of growth hormone after radiation therapy, 10 had a deficiency of gonadotropins, 4 had a deficiency of thyrotropin, and 1 had a deficiency of corticotropin.
  
  
  CONCLUSIONS
  Pituitary irradiation is an effective and well-tolerated treatment for patients with Cushing's disease in whom transsphenoidal surgery is unsuccessful.
authors.affiliation: Department of Endocrinology, Clínica Puerta de Hierro, Universidad Autónoma, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Estrada
authors.forename: M
authors.initials: M
authors.lastname: Boronat
authors.forename: M
authors.initials: M
authors.lastname: Mielgo
authors.forename: R
authors.initials: R
authors.lastname: Magallón
authors.forename: I
authors.initials: I
authors.lastname: Millan
authors.forename: S
authors.initials: S
authors.lastname: Díez
authors.forename: T
authors.initials: T
authors.lastname: Lucas
authors.forename: B
authors.initials: B
authors.lastname: Barceló
mesh_terms: D000293:Adolescent; D000328:Adult; D003480:Cushing Syndrome / Q000097:blood / Q000532:radiotherapy* / Q000601:surgery / Q000652:urine; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000601:surgery*; D010908:Pituitary Hormones, Anterior / Q000097:blood; D010910:Pituitary Irradiation / Q000009:adverse effects; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D010908:Pituitary Hormones, Anterior; D006854:Hydrocortisone